russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2016-3-97-100russjcardiol-740Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯGUIDELINES FOR THE PRACTITIONERКЛОПИДОГРЕЛ ПРИ ПЛАНОВОЙ РЕВАСКУЛЯРИЗАЦИИ МИОКАРДАCLOPIDOGREL FOR SELECTIVE MYOCARDIAL REVASCULARIZATIONТепловаН. В.TeplovaN. V.

д.м.н., профессор кафедры госпитальной терапии №1 л/ф,

Москва

Moscow

teplova.nv@yandex.ruГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н. И. Пирогова Минздрава РоссииРоссияN.I. Pirogov Russian National Research Medical UniversityRussian Federation2016280320160397100Copyright © Теплова Н.В., 20162016Теплова Н.В.Teplova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/740

В статье рассматриваются практические вопросы плановой реваскуляризации миокарда, включая особенности выбора процедуры и категории пациентов, которым это вмешательство наиболее показано. Акцент делается на антитромбоцитарной терапии, времени её проведения относительно процедуры вмешательства и рекомендуемых препаратах. Данные приводятся с позиции доказательной медицины на основании недавних Европейских рекомендаций.

The article focuses on the practical issues of selective revascularization of myocardium, including the specifics of procedure and patients characteristics, whom this intervention is at most indicated. The emphasis is done on antiplatelet therapy, its timing related to the procedure itself, and on the recommended drugs. The data is provided from the point of evidence based medicine — recent European Guidelines.

чрескожное коронарное вмешательствоаспиринацетилсалициловая кислотаклопидогрелклапитаксстабильная ишемическая болезнь сердцастенокардияpercutaneous coronary interventionaspirinacetylsalicylic acidclopidogrelclapitaxstable coronary heart diseaseanginaReferences2014 ESC/EACTS Guidelines on myocardial revascularization (Russian translation). Russ J Cardiol 2015, 2 (118): 5-81. Russian (Рекомендации ESC/EACTS по реваскуляризации миокарда 2014. Российский кардиологический журнал 2015, 2 (118): 5-81).2014 ESC/EACTS Guidelines on myocardial revascularization (Russian translation). Russ J Cardiol 2015, 2 (118): 5-81. Russian (Рекомендации ESC/EACTS по реваскуляризации миокарда 2014. Российский кардиологический журнал 2015, 2 (118): 5-81).Min JK, Dunning A, Lin FY, et al. Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease. J Am Coll Cardiol 2011; 58(8): 849-60.Min JK, Dunning A, Lin FY, et al. Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease. J Am Coll Cardiol 2011; 58(8): 849-60.Hachamovitch R, Rozanski A, Shaw LJ, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 2011; 32(8): 1012-24.Hachamovitch R, Rozanski A, Shaw LJ, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 2011; 32(8): 1012-24.Gordeev IG, Taratukhin EO, Shaydyuk OYu. Clinical Physiology and Pharmacology of Clotting. Moscow, Silicea-Poligraf, 2013, 128p. Russian (Гордеев ИГ, Таратухин ЕО, Шайдюк О.Ю. Клиническая физиология и фармакология гемостаза. М.: Силицея-Полиграф. 2013, 128с).Gordeev IG, Taratukhin EO, Shaydyuk OYu. Clinical Physiology and Pharmacology of Clotting. Moscow, Silicea-Poligraf, 2013, 128p. Russian (Гордеев ИГ, Таратухин ЕО, Шайдюк О.Ю. Клиническая физиология и фармакология гемостаза. М.: Силицея-Полиграф. 2013, 128с).Hao PP, Zhang MX, Li RJ, et al. Clopidogrel 150 vs. 75 mg per day in patients undergoing percutaneous coronary intervention: a meta-analysis. J Throm Haemost 2011 Apr; 9: 627-37.Hao PP, Zhang MX, Li RJ, et al. Clopidogrel 150 vs. 75 mg per day in patients undergoing percutaneous coronary intervention: a meta-analysis. J Throm Haemost 2011 Apr; 9: 627-37.Bonello-Palot N, Armero S, Paganelli F, et al. Relation of body mass index to high on-ntreatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009; 104: 1511-5.Bonello-Palot N, Armero S, Paganelli F, et al. Relation of body mass index to high on-ntreatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009; 104: 1511-5.Ned RM. Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availability. Application: Pharmacogenomics. PLOS Currents Evidence on Genomic Tests. 2010 Sep 20. Ed.1. doi: 10.1371/currents.RRN1180.Ned RM. Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availability. Application: Pharmacogenomics. PLOS Currents Evidence on Genomic Tests. 2010 Sep 20. Ed.1. doi: 10.1371/currents.RRN1180.Patti G, Grieco D, et al. High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelian Function, and Inflammation. Results of the ARMIDA-150 mg (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) Randomized Study. J Am Coll Cardiol 2011; 57: 771-8.Patti G, Grieco D, et al. High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelian Function, and Inflammation. Results of the ARMIDA-150 mg (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) Randomized Study. J Am Coll Cardiol 2011; 57: 771-8.

The authors declare that there are no conflicts of interest present.